keyword
MENU ▼
Read by QxMD icon Read
search

diabetic nephropathy review

keyword
https://www.readbyqxmd.com/read/28106778/methylglyoxal-glyoxalase-1-balance-the-root-of-vascular-damage
#1
REVIEW
Cecilia Nigro, Alessia Leone, Gregory Alexander Raciti, Michele Longo, Paola Mirra, Pietro Formisano, Francesco Beguinot, Claudia Miele
The highly reactive dicarbonyl methylglyoxal (MGO) is mainly formed as byproduct of glycolysis. Therefore, high blood glucose levels determine increased MGO accumulation. Nonetheless, MGO levels are also increased as consequence of the ineffective action of its main detoxification pathway, the glyoxalase system, of which glyoxalase 1 (Glo1) is the rate-limiting enzyme. Indeed, a physiological decrease of Glo1 transcription and activity occurs not only in chronic hyperglycaemia but also with ageing, during which MGO accumulation occurs...
January 18, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28096078/how-to-prevent-the-microvascular-complications-of-type-2-diabetes-beyond-glucose-control
#2
REVIEW
Willy Marcos Valencia, Hermes Florez
Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society...
January 17, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28078852/cell-based-therapies-for-experimental-diabetic-nephropathy-a-systematic-review-and-meta-analysis
#3
H J Tang, Z G Tian, X Yang, Y Cao, W G Li
Study has shown that stem cell–based therapies are promising strategies in the treatment of several chronic diseases, but their overall benefit in the treatment of diabetic nephropathy (DN) remains controversial. The purpose of this study is to summarize the evidence of the effect of cell-based therapy in the treatment of DN to guide future clinical trials. We searched PubMed, EmBase, and the Cochrane Library for studies from the inception of cell-based therapies up to July 2015. We included animal trials that reported the effects of cell-based therapy on kidney function, cardiovascular risk factors, and body factors...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28077412/microvascular-outcomes-after-metabolic-surgery-moms-in-patients-with-type-2-diabetes-mellitus-and-class-i-obesity-rationale-and-design-for-a-randomised-controlled-trial
#4
Ricardo Vitor Cohen, Tiago Veiga Pereira, Cristina Mamédio Aboud, Pedro Paulo de Paris Caravatto, Tarissa Beatrice Zanata Petry, José Luis Lopes Correa, Carlos Aurélio Schiavon, Mariangela Correa, Carlos Eduardo Pompílio, Fernando Nogueira Quirino Pechy, Carel le Roux
INTRODUCTION: There are several randomised controlled trials (RCTs) that have already shown that metabolic/bariatric surgery achieves short-term and long-term glycaemic control while there are no level 1A of evidence data regarding the effects of surgery on the microvascular complications of type 2 diabetes mellitus (T2DM). PURPOSE: The aim of this trial is to investigate the long-term efficacy and safety of the Roux-en-Y gastric bypass (RYGB) plus the best medical treatment (BMT) versus the BMT alone to improve microvascular outcomes in patients with T2DM with a body mass index (BMI) of 30-34...
January 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28073426/the-prevention-and-treatment-of-retinal-complications-in-diabetes
#5
Susanne Gabriele Schorr, Hans-Peter Hammes, Ulrich Alfons Müller, Heinz-Harald Abholz, Rüdiger Landgraf, Bernd Bertram
BACKGROUND: Microvascular complications of diabetes mellitus can cause retino pathy and maculopathy, which can irreversibly damage vision and lead to blindness. The prevalence of retinopathy is 9-16% in patients with type 2 diabetes and 24-27% in patients with type 1 diabetes. 0.2-0.5% of diabetics are blind. METHODS: The National Disease Management Guideline on the prevention and treatment of retinal complications in diabetes was updated according to recommendations developed by seven scientific medical societies and organizations and by patient representatives and then approved in a formal consensus process...
December 2, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28072721/total-bilirubin-level-may-be-a-biomarker-of-nephropathy-in-type-2-diabetes-mellitus-a-meta-analysis-of-observational-studies-based-on-moose-compliant
#6
Dan Zhang, Bo Zhu, Wei Zhang, Wei Wang, Dan Guo, Ligang Yang, Lu Wang
Recently, the number of the studies on the relationship between the total bilirubin level (TBL) and diabetic nephropathy (DN) is increasing, but their results were not consistent. Therefore, we performed a meta-analysis to analyze the relationship between TBL and the risk of DN.We searched 5 databases before October 31, 2016, and reviewed the reference list of relevant articles. The fixed or random-effects model was used to pool risk estimates. We conducted the dose-response meta-analysis to evaluate the relationship between TBL and the risk of DN...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28055075/oral-pharmacologic-treatment-of-type-2-diabetes-mellitus-a-clinical-practice-guideline-update-from-the-american-college-of-physicians
#7
Amir Qaseem, Michael J Barry, Linda L Humphrey, Mary Ann Forciea
Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes...
January 3, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28052873/path-of-translational-discovery-of-urological-complications-of-obesity-and-diabetes-ucod
#8
Firouz Daneshgari, Guiming Liu, Ann T Hanna-Mitchell
Diabetes Mellitus (DM) is a prevalent chronic disease. Type 1 diabetes mellitus (T1DM) is a metabolic disorder that is characterized by hyperglycemia in the context of absolute lack of insulin; whereas type 2 diabetes mellitus (T2DM) is due to insulin resistance-related relative insulin deficiency. Obesity is an established risk factor for T2DM. In comparison with T1DM, T2DM is more complex. The natural history of T2DM in most patients typically involves a course of obesity to impaired glucose tolerance, to insulin resistance and hyperglycemia...
January 4, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28051871/modulating-mineralocorticoid-receptor-with-non-steroid-antagonists-new-opportunities-for-the-development-of-potent-and-selective-ligands-without-off-target-side-effects
#9
Mercedes Martín-Martínez, Felipe Luis Pérez-Gordillo, Diego Alvarez De la Rosa, Yoel Rodríguez, Guillermo Gerona-Navarro, Rosario González-Muñiz, Ming-Ming Zhou
Steroidal mineralocorticoid receptor (MR) antagonists are used for treatment of a range of human diseases, but present challenging issues of complex chemical synthesis, undesirable physical properties and poor selectivity along with unwanted side effects. Therefore, there is a great interest in the discovery of non-steroidal ligands able to bind to the ligand-binding domain (LBD) of the MR, and recruit different coregulators to produce tissue-specific therapeutic effects. Several academic groups and pharmaceutical companies have been developing a series of non-steroidal ligands that consist of different chemical scaffolds, yielding MR antagonists currently evaluated in clinical studies for the treatment of congestive heart failure, hypertension or diabetic nephropathy...
January 4, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28049280/new-therapeutic-agents-in-diabetic-nephropathy
#10
REVIEW
Yaeni Kim, Cheol Whee Park
Studies investigating diabetic nephropathy (DN) have mostly focused on interpreting the pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease onset and progression. Currently, there are few therapeutic drugs for DN, which mainly consist of antihypertensive and antiproteinuric measures that arise from strict renin-angiotensin-aldosterone system inactivation. However, these traditional therapies are suboptimal and there is a clear, unmet need for treatments that offer effective schemes beyond glucose control...
January 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28040287/race-and-contrast-induced-nephropathy-in-patients-undergoing-coronary-angiography-and-cardiac-catheterization
#11
REVIEW
Raveen Chawla, Jeremy Turlington, Pradeep Arora, Ion S Jovin
Contrast-induced nephropathy (CIN) is an acute worsening of renal function after receiving intravascular contrast during a procedure. Some of the predisposing factors include underlying diabetes, chronic kidney disease, congestive heart failure, periprocedural hypotension, anemia, contrast volume, and osmolality of contrast; however, it remains unclear if risk varies for CIN with race and ethnicity. There is evidence in the literature showing the link between race/ethnicity and the discrepancies in the utilization of preventive care services and the resources related to cardiovascular and renal health...
December 23, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28034290/marine-algae-as-a-prospective-source-for-antidiabetic-compounds-a-brief-review
#12
S P Unnikrishnan, A M Jayasri
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycaemia, which is attributed by several life threatening complications including atherosclerosis, nephropathy, and retinopathy. The current therapies available for the management of DM mainly include oral antidiabetic drugs and insulin injections. However, continuous use of synthetic drugs provides lower healing with many side effects. Therefore, there is an urge for safe and efficient antidiabetic drugs for the management of DM...
December 29, 2016: Current Diabetes Reviews
https://www.readbyqxmd.com/read/28009969/the-role-of-connexin43-in-diabetic-microvascular-complications
#13
Hui Li, Fang Wang
Diabetes mellitus is one of the largest global healthcare problems. People with diabetes have high risk of developing any of the microvascularcomplications, including retinopathy, nephropathy, and neuropathy, which can bring much more serious psychological and economic burden for the diabetic patients. As a consequence of its microvascular complications, diabetes has become the leading cause of blindness, end-stage renal disease, and a variety of debilitating neuropathies. Although the mechanisms involved in the development and progression of these three diabetic microvascular complications are different and have not been completely elucidated, some common histopathological features like increased vascular permeability and apoptosis of specific vascular cells are shared in retinopathy and nephropathy...
November 2016: Discovery Medicine
https://www.readbyqxmd.com/read/27994440/use-of-bedaquiline-and-delamanid-in-diabetes-patients-clinical-and-pharmacological-considerations
#14
REVIEW
Minhui Hu, Chunlan Zheng, Feng Gao
Antituberculosis (anti-TB) treatment may be affected by both diabetes and hypoglycemic agents in patients with these 2 comorbidities. However, data supporting this conclusion relate only to standard anti-TB therapies. Sirturo(®) (bedaquiline) and Deltyba(®) (delamanid), novel drugs for multidrug-resistant tuberculosis (MDR-TB), are recommended for diabetes patients when another effective treatment regimen cannot be provided. Currently, there are no clinical data related to the use of these agents in diabetes patients...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27971364/albuminuria-and-serum-creatinine-in-predicting-renal-function-decline-in-patients-with-diabetic-nephropathy-a-systematic-literature-review
#15
E Grubb, J Van der Vaart, K Norris, K E Smoyer, C Rolland
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27951538/colchicine-in-renal-medicine-new-virtues-of-an-ancient-friend
#16
Yalcin Solak, Dimitrie Siriopol, Abdulmecit Yildiz, Mahmut Ilker Yilmaz, Alberto Ortiz, Adrian Covic, Mehmet Kanbay
Colchicine is a plant-derived alkaloid that disrupts the cell microtubule system and accumulates in neutrophils, inhibiting neutrophil adhesion and recruitment. Colchicine has been used extensively in the prevention and treatment of gouty arthritis attacks, familial Mediterranean fever attacks and resultant AA amyloidosis, and recurrent pericarditis. Colchicine also disrupts the intracellular traffic of additional inflammatory and fibrosis mediators. Renal fibrosis is the final common pathway of chronic renal disease...
December 13, 2016: Blood Purification
https://www.readbyqxmd.com/read/27939359/a-story-of-metformin-butyrate-synergism-to-control-various-pathological-conditions-as-a-consequence-of-gut-microbiome-modification-genesis-of-a-wonder-drug
#17
REVIEW
Kunal Maniar, Amal Moideen, Ankur Mittal, Amol Patil, Amitava Chakrabarti, Dibyajyoti Banerjee
The most widely prescribed oral anti-diabetic agent today in the world today is a member of the biguanide class of drugs called metformin. Apart from its use in diabetes, it is currently being investigated for its potential use in many diseases such as cancer, cardiovascular diseases, Alzheimer's disease, obesity, comorbidities of diabetes such as retinopathy, nephropathy to name a few. Numerous in-vitro and in-vivo studies as well as clinical trials have been and are being conducted with a vast amount of literature being published every day...
December 8, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27935823/renal-disease-pathophysiology-and-treatment-contributions-from-the-rat
#18
REVIEW
Linda J Mullins, Bryan R Conway, Robert I Menzies, Laura Denby, John J Mullins
The rat has classically been the species of choice for pharmacological studies and disease modeling, providing a source of high-quality physiological data on cardiovascular and renal pathophysiology over many decades. Recent developments in genome engineering now allow us to capitalize on the wealth of knowledge acquired over the last century. Here, we review rat models of hypertension, diabetic nephropathy, and acute and chronic kidney disease. These models have made important contributions to our understanding of renal diseases and have revealed key genes, such as Ace and P2rx7, involved in renal pathogenic processes...
December 1, 2016: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/27903991/role-of-oxidative-stress-and-inflammatory-factors-in-diabetic-kidney-disease
#19
Esmat Aghadavod, Samaneh Khodadadi, Azar Baradaran, Parto Nasri, Mahmood Bahmani, Mahmoud Rafieian-Kopaei
Diabetic nephropathy (DN) is a serious complication of diabetes mellitus, and its prevalence has been increasing in developed countries. Diabetic nephropathy has become the most common single cause of end-stage renal disease worldwide. Oxidative stress and inflammation factors are hypothesized to play a role in the development of late diabetes complications. Chronic hyperglycemia increases oxidative stress, significantly modifies the structure and function of proteins and lipids, and induces glycoxidation and peroxidation...
November 2016: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/27894247/aldose-reductase-as-a-drug-target-for-treatment-of-diabetic-nephropathy-promises-and-challenges
#20
Heba El Gamal, Shankar Munusamy
Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes mellitus and the leading cause of end stage renal disease. One of the key pathways activated in DN is the polyol pathway, in which glucose is converted to sorbitol (a relatively non-metabolizable sugar) by the enzyme aldose reductase (AR). Shunting of glucose into this pathway causes disruption to glucose metabolism and subsequently damages the tissues via increased oxidative stress, protein kinase c activation and production of advanced glycation end products (AGE) in the kidney...
November 28, 2016: Protein and Peptide Letters
keyword
keyword
69140
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"